Therapeutic Advances in Drug Safety

Papers
(The H4-Index of Therapeutic Advances in Drug Safety is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews46
Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination21
Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance20
Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review20
The danger of diazoxide in the neonatal intensive care unit18
The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and 17
Anticholinergic burden measures and older people’s falls risk: a systematic prognostic review15
Attitudes of ambulatory care older Nepalese patients towards deprescribing and predictors of their willingness to deprescribe14
Pharmacovigilance: reporting requirements throughout a product’s lifecycle14
The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review13
Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge13
Systematic review of immunosuppressant guidelines in the COVID-19 pandemic12
0.043681144714355